Prevalence of HLA-B*58:01 allele among Malay, Chinese and Indian ethnic patients with gout attending primary care clinics in Malaysia.

Autor: Ng WL; Department of Primary Care Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia. wlng@ummc.edu.my., Kee BP; Department of Biomedical Science, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia., Hussein N; Department of Primary Care Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia., Ng CJ; Department of Primary Care Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.; Department of Research, SingHealth Polyclinics, Singapore, Singapore.; Health Services and Systems Research, Duke-NUS Medical School, Singapore, Singapore., Kuan SW; Department of Biomedical Science, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia., Mohd Zaidan FZ; Tanglin Health Clinic, Ministry of Health Malaysia, Kuala Lumpur, Malaysia., Azmi SUF; Taman Ehsan Health Clinic, Ministry of Health Malaysia, Selangor, Malaysia., Then SM; Division of Biomedical Science, School of Pharmacy, Faculty of Science and Engineering, University of Nottingham Malaysia, Selangor, Malaysia., Kwan Z; Division of Dermatology, Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia., Qureshi N; Division of Primary Care, School of Medicine, University of Nottingham, NG7 2RD, Nottingham, UK., Lim JR; Department of Primary Care Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia., Wong LY; Department of Primary Care Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia., Lee YK; Department of Primary Care Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia., Abdul Malik TF; Department of Primary Care Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia., Gunasekaran R; Division of Dermatology, Department of Medicine, Hospital Tengku Ampuan Rahimah, Ministry of Health Malaysia, Selangor, Malaysia., Low DE; Division of Dermatology, Department of Medicine, Hospital Serdang, Ministry of Health Malaysia, Selangor, Malaysia.
Jazyk: angličtina
Zdroj: Journal of community genetics [J Community Genet] 2024 Nov 25. Date of Electronic Publication: 2024 Nov 25.
DOI: 10.1007/s12687-024-00753-4
Abstrakt: HLA-B*58:01 allele is associated with allopurinol-induced severe cutaneous reaction (SCAR). Malaysia has a multiethnic population with limited data on the prevalence of HLA-B*58:01 among patients with gout treated in primary care settings. This cross-sectional study aimed to determine the prevalence of HLA-B*5801 in patients with gout from the Malay, Chinese and Indian ethnicities attending primary clinics in Malaysia.We collected blood samples from patients with gout attending three primary care clinics in Klang Valley, Malaysia, using convenience sampling. Genomic DNA samples were subjected to typing of HLA-B*5801 by a multiplex probe-based assay in a real-time PCR system, validated by PCR-resequencing approach.547 patients (194 Malay, 266 Chinese and 87 Indian) were recruited. The overall prevalence of HLA-B*58:01 was 16.8% (Chinese 21.8%, Indian 12.6% and Malay 11.9%). None of our 61 HLA-B*58:01 carriers who ever used allopurinol developed SCAR.The overall prevalence of HLA-B*58:01 allele in our patients with gout was high, particularly among the Chinese ethnicity (21.8%). None of our HLA-B*58:01 positive patients treated with allopurinol reported allopurinol-induced SCAR. A more accurate predictive model for allopurinol-induced SCAR is needed.
Competing Interests: Declarations. Conflict of interest: One of our authors, Professor Nadeem Qureshi serves on the advisory board for Journal of Community Genetics. The rest of the authors have no competing interest. Compliance with ethics guidelines: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study. This study was approved by the UMMC Ethics Committee (MREC ID NO: 2020224–8313) and the Medical Research and Ethics Committee, Ministry of Health Malaysia (NMRR-20–1612-53782).
(© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: